Table 4 Changes in pre-treatment resting parameters during pulmonary rehabilitation with ghrelin or placebo
|  | Ghrelin, n = 10 | Placebo, n = 10 | Treatment effect (95% CI; p value†) | ||
|---|---|---|---|---|---|
| Â | Pre-treatment | Mean D. | Pre-treatment | Mean D. | Â |
Body weight (kg) | 48.2 (7.4) | -0.1 (1.0) | 46.8 (7.6) | 0.1 (1.3) | -0.2 (-1.3 to 0.9; 0.698) |
Total lean mass (kg) | 37.2 (5.6) | 0.1 (2.3) | 35.5 (4.7) | 0.6 (0.8) | -0.5 (-2.1 to 1.2; 0.561) |
MEP‡ (cmH20) | 77.7 (28.7) | 16.2 (15.8) | 87.2 (25.6) | -6.6 (13.4) | 22.8 (7.1 to 38.4; 0.007) |
MIP‡ (cmH20) | -52.7 (20.8) | -10.0 (24.6) | -54.2 (15.4) | -7.9 (5.4) | -2.1 (-22.5 to 18.2; 0.825) |
PFT | Â | Â | Â | Â | Â |
FEV1 (L) | 0.83 (0.21) | 0.06 (0.16) | 0.82 (0.23) | 0.07 (0.16) | -0.01 (-0.16 to 0.13; 0.845) |
FEV1/FVC (%) | 41.7 (7.6) | -1.9 (3.6) | 42.4 (8.0) | -3.4 (3.8)* | 1.5 (-2.1 to 5.0; 0.383) |
%FEV1 (%) | 32.0 (9.4) | 2.1 (6.3) | 33.3 (10.5) | 2.9 (6.3) | -0.8 (-6.8 to 5.1; 0.778) |
VC (L) | 2.54 (0.42) | 0.18 (0.28) | 2.62 (0.50) | 0.15 (0.20)* | 0.03 (-0.20 to 0.26; 0.800) |
%VC (%) | 79.6 (11.0) | 5.5 (8.9) | 86.1 (15.3) | 4.9 (7.3) | 0.6 (-7.1 to 8.2; 0.877) |
DLco (%) | 61.3 (23.8) | 10.0 (37.5) | 72.4 (27.4) | -6.1 (12.2) | 16.1 (-10.1 to 42.3; 0.222) |